Individuals
This is the only test which quantifies biological differences in cellular lipid uptake and storage and thus provides unique information about individual responses to cholesterol-lowering therapy. The readouts are derived from white blood cells, including monocytes, key cells that set off inflammation in the plaques of the artery wall, providing additional insight into cardiovascular risk.
Phycisians
The MONCYTE Test aims to provide an optimal treatment recommendation for cholesterol-lowering therapy at the start of the therapy. This may enable more rapid and effective cholesterol-lowering. After initiation of cholesterol-lowering therapy, the MONCYTE Test can help in identifying subjects that are at elevated risk and are in need of more effective cholesterol-lowering therapy, such as combination therapy with ezetimibe, bempadoic acid, or PCSK9i.
Pharmaceutical and biotech companies
MONCYTE Health technology offers a more specific and pragmatic approach to measuring the residual risk due to high levels of LDL or other atherogenic lipoproteins as compared to other available approaches and can easily be incorporated into clinical trial programs. The MONCYTE Test quantitatively assesses the interaction of atherogenic lipoprotein particles with monocytes and is thus providing additional readouts for estimating residual cardiovascular risk. Furthermore, because this test involves only a blood sample collection with simple processing at the clinical site, it is much easier to incorporate into clinical protocols and less expensive than existing imaging approaches to provide information about cardiovascular risk.